



#13

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Khan et al.

Serial No.: 10/029,206

Filed: December 21, 2001

For: OLIGOPEPTIDE TREATMENT OF
ANTHRAX

Examiner: To be assigned

Group Art Unit: 1651

Attorney Docket No.: 2183-5222US

NOTICE OF EXPRESS MAILING

Express Mail Mailing Label Number: EV175437526US

Date of Deposit with USPS: October 15, 2002

Person making Deposit: Orlena Howell

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:

In compliance with the duty to disclose information material to patentability pursuant to 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 or PTO/SB/08 be considered by the Examiner and made of record. Copies of the listed documents are enclosed pursuant to 37 C.F.R. § 1.98(a).

In accordance with 37 C.F.R. § 1.97(g) and (h), filing of this Information Disclosure Statement is not to be construed as a representation that a search has been made or an admission that the information cited herein is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b). Further, no representation is made by Applicants herein that no other possible material information as defined in 37 C.F.R. § 1.56(b) exists.

Serial No.: 10/029,206

Foreign Patent Documents

| <u>Document No.</u> | <u>Publication Date</u> | <u>Patentee</u> |
|---------------------|-------------------------|------------------------|
| WO 99/59617 | 11-25-1999 | Erasmus Universiteit |
| WO 97/49721 | 12-31-1997 | University of Maryland |

Other Documents

PCT International Search Report, PCT/NL01/00259, dated December 18, 2001, 3 pages.

PCT International Preliminary Examination Report, PCT/NL99/00313, dated July 21, 2000, 6 pages.

PCT International Search Report, PCT/EP99/00313, dated November 29, 1999, 3 pages.

Lang et al., "Induction of apoptosis in Kaposi's sarcoma spindle cell cultures by the subunits of human chorionic gonadotropin", AIDS 1997, Vol. 11, No. 11, pp.1333-1340.

Iskandar et al., "Effects of a urinary factor from women in early pregnancy on HIV-1. SIV and associated disease", Nature Medicine, April 1998, Vol. 4, No. 4, pp. 428-434.

In compliance with the duty to disclose information material to patentability pursuant to 37 C.F.R. § 1.56 & 1.175, applicant hereby identifies the following listed copending applications naming the same inventor(s):

Attorney Docket No.: 2183-4618US
Serial No.: 09/716,777
Filing Date: 11/20/2000
For: IMMUNOREGULATOR

Attorney Docket No.: 2183-4799US
Serial No.: 09/821,380
Filing Date: 3/29/2001
For: IMMUNOREGULATOR

Serial No.: 10/029,206

Attorney Docket No.: 2183-5223US
Serial No.: 10/028,075
Filing Date: 12/21/2001
For: GENE REGULATOR

Attorney Docket No.: 2183-5526US
Serial No.: To be assigned
Filing Date: 9/30/2002
For: IMMUNOREGULATOR

This Information Disclosure Statement is believed to be filed before the mailing date of the first Office Action on the merits, and no certification pursuant to 37 C.F.R. § 1.97(c) or a fee pursuant to 37 C.F.R. § 1.17(p) is required.

Respectfully submitted,



Allen C. Turner
Registration No. 33,041
Attorney for Applicant(s)
TRASKBRITT, PC
P.O. Box 2550
Salt Lake City, Utah 84110-2550
Telephone: 801-532-1922

Date: October 11, 2002
ACT/bv
Enclosures: Form PTO-1449 or PTO/SB/08
Cited Documents
Document in ProLaw

| | | | |
|-------|---|----|---|
| Sheet | 1 | of | 2 |
|-------|---|----|---|

| | |
|------------------------|-------------------|
| Application Number | 10/029,206 |
| Filing Date | December 21, 2001 |
| First Named Inventor | Khan et al. |
| Group Art Unit | 1651 |
| Examiner Name | To be assigned |
| Attorney Docket Number | 2183-5222US |

[illegible][illegible]Date
Considered

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Commissioner for Patents, Washington, DC 20231.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 2

Complete if Known

| | |
|------------------------|-------------------|
| Application Number | 10/029,206 |
| Filing Date | December 21, 2001 |
| First Named Inventor | Khan et al. |
| Group Art Unit | 1651 |
| Examiner Name | To be assigned |
| Attorney Docket Number | 2183-5222US |

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|------------------------|--------------------------|---|----------------|
| | | PCT International Search Report, PCT/NL01/00259, dated December 18, 2001, 3 pages. | |
| | | PCT International Preliminary Examination Report, PCT/NL99/00313, dated July 21, 2000, 6 pages. | |
| | | PCT International Search Report, PCT/EP99/00313, dated November 29, 1999, 3 pages. | |
| | | Lang et al., "Induction of apoptosis in Kaposi's sarcoma spindle cell cultures by the subunits of human chorionic gonadotropin", <u>AIDS</u> 1997, Vol. 11, No. 11, pp.1333-1340. | |
| | | Iskandar et al., "Effects of a urinary factor from women in early pregnancy on HIV-1. SIV and associated disease", <u>Nature Medicine</u> , April 1998, Vol. 4, No. 4, pp. 428-434. | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.